

LYNX THERAPEUTICS INC

Form 8-K

May 13, 2004

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D. C. 20549**

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 13, 2004

Date of Filing: May 13, 2004

**Lynx Therapeutics, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**0-22570**

(Commission File No.)

**94-3161073**

(IRS Employer Identification No.)

**25861 Industrial Blvd.**

**Hayward, California 94545**

(Address of Principal Executive Offices and Zip Code)

Registrant's telephone number, including area code: **(510) 670-9300**

---

**TABLE OF CONTENTS**

Item 12. Results of Operations and Financial Condition

SIGNATURE

EXHIBIT 99.1

---

**Table of Contents**

**Item 12. Results of Operations and Financial Condition**

On May 13, 2004, Lynx Therapeutics, Inc. issued a press release announcing financial results for the three months ended March 31, 2004. A copy of such press release, entitled "Lynx Announces First Quarter Financial Results," is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this report, including the exhibit hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Lynx Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**LYNX THERAPEUTICS, INC.**

Dated: May 13, 2004

By: /s/ Kevin P. Corcoran  
Kevin P. Corcoran  
President and Chief Executive Officer  
(Principal Executive Officer)

---

**Table of Contents**

**INDEX TO EXHIBITS**

- 99.1 Press release entitled Lynx Announces First Quarter Financial Results, dated May 13, 2004.